PRVB News and Press, Provention Bio Inc. From 11/06/20

Image source: The Motley Fool. Provention Bio, Inc (NASDAQ: PRVB) Q3 2020 Earnings Call Nov 6, 2020 , 8:00 p.m. ET Operator Continue reading For further details see: Provention Bio, Inc (PRVB) Q3 2020 Earnings Call Transcript

Provention Bio (PRVB): Q3 GAAP EPS of -$0.56 misses by $0.14.Cash, cash equivalents and marketable securities of $147.2MPress Release For further details see: Provention Bio EPS misses by $0.14

Provention Bio Reports Third Quarter 2020 Financial Results and Provides Business Update - Completed rolling submission of the Biologics License Application (BLA) for teplizumab in the delay or prevention of clinical type 1 diabetes (T1D) in at-risk individuals - - Launched ...

Provention is leading a set of new drugs that protect beta cell functions, enabling endogenous insulin production in type 1 diabetes patients. The stock may have a PDUFA late next year; rolling BLA submission is complete. Financials and insider interest look good. For furthe...

Provention Bio (PRVB) has completed its rolling U.S. marketing application for teplizumab for the delay or prevention of clinical type 1 diabetes (T1D) in at-risk people, a Breakthrough Therapy-tagged indication. The company has requested Priority Review which, if granted, will shorten the re...

Provention Bio Completes Rolling Submission of the Biologics License Application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals - Submission of chemistry, manufacturing and controls (CMC) and administrative information modules...

Provention Bio to Report Third Quarter 2020 Financial Results and Host Conference Call on Thursday, November 5, 2020 PR Newswire RED BANK, N.J., Oct. 29, 2020 RED BANK, N.J. , Oct. 29, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharma...

Gainers: [[DSS]] +26.5%. [[PRVB]] +8.4%. [[GRTS]] +4.7%. [[LILA]] +3.4%. [[NVTA]] +3.1%.Losers: [[ATHM]] -6.9%. [[MRIN]] -5.2%. [[CRMD]] -3.8%. [[QLYS]] -3.3%. [[CBAY]] -2.3%. For further details see: DSS, PRVB, ATHM and QLYS among after-hours movers

Provention Bio Announces National Effort to Redefine Patient Care in Type 1 Diabetes (T1D) - Healthcare professional and patient campaigns focus on screening for early-stage T1D- PR Newswire RED BANK, N.J., Oct. 1, 2020 RED BANK, N.J. , Oct. 1, 2020 /PRNe...

Provention Bio (PRVB) reports that it has filed the clinical module of its rolling U.S. marketing application for teplizumab (PRV-031) for the delay or prevention of type 1 diabetes (T1D) in at-risk people.It initiated the process in April with the submission of the nonclinical module. It exp...